RxDoctor Payments Data

Scott Sanderson, MD

Ophthalmology · Edina, MNNPI 1093755282

Payments from drug & device makers

$351in general payments, 2019–2025

Across 15 payments — averaging $23.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$126
  • Novartis$68
  • Glaukos Corporation$25
  • AbbVie$22
  • Carl Zeiss Meditec AG$19
  • Carl Zeiss Meditec, Inc.$17
  • plus $73 from 5 others

What the payments were for

  • Food & beverage$31490%
  • Gifts$3710%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$351 in reported general payments places this provider in the 50th percentile of 330 ophthalmology providers in Minnesota.

See all ophthalmology providers in Minnesota

Medicare billing

Part B allowed, 2024
$329,097
Medicare patients
988
Services billed
2,741

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine58$73,149
Latanoprost1,340$27,199
LumiganBimatoprost26$18,836
RhopressaNetarsudil Mesylate21$13,891
Cyclosporine23$12,715
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat355$9,481
Brimonidine Tartrate102$6,270
Timolol Maleate241$4,284
Fluorometholone38$3,003
Tobramycin-DexamethasoneTobramycin/Dexamethasone40$1,686
Doxycycline Hyclate44$1,527
Atropine Sulfate29$1,045
Prednisolone Acetate15$915
Dorzolamide Hcl25$518
Ketorolac Tromethamine11$104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$22$91,98584 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 330 ophthalmology providers in Minnesota.

Other ophthalmology in Edina

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →